Peptides Similar to MOTS-c

Peptides Related to MOTS-c#

MOTS-c belongs to the family of mitochondrial-derived peptides (MDPs), a class of biologically active molecules encoded within the mitochondrial genome. Several other peptides share functional or structural overlap with MOTS-c in targeting mitochondrial pathways, metabolic regulation, or cellular stress responses. This article compares MOTS-c with the most closely related peptides, examining their mechanisms, research status, and potential applications.

Mitochondrial-Derived Peptide Family#

MOTS-c, humanin, and the SHLP peptides together constitute the known mitochondrial-derived peptide family. All are encoded within short open reading frames (sORFs) in mitochondrial ribosomal RNA genes, and all function as signaling molecules that communicate mitochondrial status to other cellular compartments. Despite this shared origin, each MDP activates distinct downstream pathways and has different primary biological effects.

SS-31 (Elamipretide)#

SS-31, also known as elamipretide or Bendavia, is a synthetic mitochondria-targeted tetrapeptide with the sequence D-Arg-Dmt-Lys-Phe-NH2 (where Dmt is 2',6'-dimethyltyrosine). Unlike MOTS-c, SS-31 is not encoded in the mitochondrial genome and is not an endogenous peptide. It was rationally designed to target the inner mitochondrial membrane by binding to cardiolipin, a phospholipid critical for the structural integrity and function of electron transport chain complexes.

Mechanistic differences. The mechanism of SS-31 is fundamentally distinct from MOTS-c. SS-31 concentrates approximately 1000-fold at the inner mitochondrial membrane, where it stabilizes cardiolipin-dependent cristae architecture, optimizes electron transport, and reduces the generation of reactive oxygen species (ROS). MOTS-c, by contrast, acts primarily through inhibition of the folate cycle enzyme MTHFD2, leading to AICAR accumulation and AMPK activation, with additional direct effects through nuclear translocation and chromatin interaction.

Clinical development. SS-31 has progressed substantially further in clinical development than MOTS-c. It has been evaluated in multiple Phase 2 and Phase 3 clinical trials for conditions including primary mitochondrial myopathy (Barth syndrome), heart failure with preserved ejection fraction, and age-related macular degeneration. Human pharmacokinetic and safety data are available. MOTS-c remains entirely in the preclinical stage with no human clinical trials completed.

Overlap and complementarity. Both SS-31 and MOTS-c aim to improve mitochondrial function, but through entirely different mechanisms. SS-31 directly supports the bioenergetic machinery of the inner mitochondrial membrane, while MOTS-c modulates cellular metabolism through AMPK-dependent signaling and nuclear gene regulation. In principle, these mechanisms could be complementary, as they target different aspects of mitochondrial and cellular physiology. However, no combination studies have been reported.

Humanin#

Humanin is a 24-amino acid peptide encoded within the mitochondrial 16S ribosomal RNA gene (MT-RNR2). It was discovered in 2001, making it the first identified mitochondrial-derived peptide and predating the discovery of MOTS-c by approximately 14 years. Humanin has been studied primarily for its cytoprotective and anti-apoptotic properties, particularly in the context of neurodegenerative diseases.

Mechanistic differences. Humanin's primary mechanism involves binding to insulin-like growth factor binding protein 3 (IGFBP-3) and the pro-apoptotic protein BAX, inhibiting apoptotic signaling cascades. Humanin also signals through the formyl peptide receptor-like 1 (FPRL1) and a trimeric receptor complex involving CNTFR, WSX-1, and gp130, activating STAT3 signaling. These mechanisms are distinct from MOTS-c's folate cycle inhibition and AMPK activation. While both peptides have metabolic effects, humanin's primary activity is anti-apoptotic and neuroprotective, whereas MOTS-c's primary activity is metabolic regulation and energy homeostasis.

Shared features. Both humanin and MOTS-c are maternally inherited through mitochondrial DNA, both circulate in plasma, and both show age-related declines in circulating levels. Both have been associated with longevity and age-related disease in epidemiological studies. Humanin levels, like MOTS-c levels, correlate inversely with age and metabolic disease markers.

Research maturity. Humanin has a longer publication history with a broader range of preclinical studies, particularly in Alzheimer's disease, cardiovascular protection, and metabolic regulation. Synthetic analogs of humanin with enhanced potency (such as HNG, or humanin with a S14G substitution) have been developed. Neither peptide has completed human clinical efficacy trials, though humanin has been more extensively characterized as a circulating biomarker in human cohort studies.

SHLP Peptides (Small Humanin-Like Peptides 1-6)#

The SHLP peptides (SHLP1 through SHLP6) are a family of six mitochondrial-derived peptides also encoded within the 16S rRNA gene (MT-RNR2), the same gene that encodes humanin. They were identified by Cobb et al. in 2016 through systematic analysis of potential sORFs in mitochondrial ribosomal RNA sequences.

Diversity of function. Each SHLP peptide has distinct biological properties. SHLP2, SHLP3, and SHLP6 have demonstrated cytoprotective effects, while SHLP2 and SHLP3 additionally show metabolic regulatory properties. SHLP4 has been reported to promote cell death in certain contexts, contrasting with the pro-survival effects of the other family members. This functional diversity within a single peptide family illustrates the complexity of mitochondrial-derived peptide signaling.

Comparison with MOTS-c. The SHLPs share with MOTS-c a mitochondrial genome origin, age-related decline in circulating levels, and roles in metabolic regulation. However, MOTS-c's mechanism through folate cycle inhibition and AMPK activation is distinct from the mechanisms described for individual SHLP peptides. MOTS-c is also better characterized than most SHLPs, with more published studies elucidating its molecular mechanism and preclinical effects. The SHLPs represent an earlier stage of research compared to MOTS-c.

Key Distinguishing Features of MOTS-c#

Several properties distinguish MOTS-c from related peptides:

• Exercise mimetic activity. MOTS-c is uniquely characterized as an exercise mimetic among the mitochondrial-derived peptides. Its ability to reproduce molecular signatures of exercise, including AMPK activation, enhanced fatty acid oxidation, and improved glucose disposal, has not been attributed to humanin, SHLPs, or SS-31 in the published literature.

• Nuclear translocation. MOTS-c's ability to translocate from mitochondria to the nucleus under stress conditions, where it directly interacts with chromatin and regulates gene expression, is a distinctive feature not shared by other MDPs or SS-31. This represents a direct retrograde signaling mechanism from the mitochondrial genome to nuclear gene regulation.

• Folate cycle targeting. The specific inhibition of MTHFD2 and consequent AICAR accumulation is unique to MOTS-c among the peptides discussed here. This mechanism links MOTS-c to one-carbon metabolism in a way that does not apply to humanin, SHLPs, or SS-31.

• Metabolic focus. While humanin is primarily studied for neuroprotection and anti-apoptosis, and SS-31 for bioenergetic support, MOTS-c's primary research focus is on metabolic homeostasis, insulin sensitivity, and energy regulation.

Evidence Gaps#

No head-to-head comparison studies have been conducted between MOTS-c and any of the peptides described above. All comparisons presented here are based on independent studies with different experimental designs, species, doses, and endpoints, limiting the ability to draw direct efficacy comparisons. Combination studies examining potential synergistic or antagonistic interactions between MOTS-c and other mitochondrial-targeting peptides have not been published. The relative therapeutic potential of these peptides for specific clinical indications cannot be assessed in the absence of comparative data and human clinical trial results.

Related Reading#

• MOTS-c overview and research guide
• MOTS-c research evidence
• MOTS-c dosing protocols